Aptose Biosciences Inc. Signs Material Definitive Agreement
Ticker: APTOF · Form: 8-K · Filed: Nov 25, 2025 · CIK: 882361
Sentiment: neutral
Topics: material-agreement, corporate-actions
TL;DR
Aptose Bio just signed a big deal, filing an 8-K on Nov 18, 2025.
AI Summary
Aptose Biosciences Inc. entered into a material definitive agreement on November 18, 2025. The company, previously known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is a biological products company based in Toronto, Canada.
Why It Matters
This filing indicates a significant new contract or partnership for Aptose Biosciences, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce significant opportunities or risks depending on their terms, which are not detailed in this initial filing.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- November 18, 2025 (date) — Date of earliest event reported
- Lorus Therapeutics Inc. (company) — Former company name
- Imutec Pharma Inc. (company) — Former company name
- Toronto, Canada (location) — Business and mail address
FAQ
What is the nature of the material definitive agreement entered into by Aptose Biosciences Inc. on November 18, 2025?
The filing states that Aptose Biosciences Inc. entered into a material definitive agreement on November 18, 2025, but the specific details of the agreement are not provided in this initial 8-K filing.
What were Aptose Biosciences Inc.'s previous names?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. (name change effective September 5, 2014) and prior to that, Imutec Pharma Inc. (name change effective January 13, 1997).
Where is Aptose Biosciences Inc. located?
Aptose Biosciences Inc. is located in Toronto, Canada, with its business and mail addresses at 66 Wellington Street West, Suite 5300, TD Bank Tower Box 48.
What is the SIC code for Aptose Biosciences Inc.?
The Standard Industrial Classification (SIC) code for Aptose Biosciences Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
When was this 8-K filing submitted?
This 8-K filing was filed as of November 25, 2025, with the date of the earliest event reported being November 18, 2025.
Filing Stats: 1,904 words · 8 min read · ~6 pages · Grade level 17 · Accepted 2025-11-24 21:43:22
Key Financial Figures
- $2.41 — t hold any Common Shares, will receive C$2.41 in cash per Common Share, which represe
- $1.88 — 28% over the Company's 30-day VWAP of C$1.88 on the Toronto Stock Exchange (" TSX ")
- $300,000 — e Arrangement Agreement provides for a C$300,000 expense fee payable to Hanmi Purchaser
Filing Documents
- d25723d8k.htm (8-K) — 37KB
- d25723dex21.htm (EX-2.1) — 856KB
- 0001193125-25-294108.txt ( ) — 1161KB
- gnw-20251118.xsd (EX-101.SCH) — 3KB
- gnw-20251118_lab.xml (EX-101.LAB) — 16KB
- gnw-20251118_pre.xml (EX-101.PRE) — 10KB
- d25723d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements This Form 8-K contains forward-looking statements or information (collectively, " forward-looking statements ") within the meaning of applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. All statements, except for statements of historical fact, that relate to the Arrangement and the anticipated future activities, plans, strategies, objectives or expectations of the Company are forward-looking statements. When used in this Form 8-K, the use of words and phrases including "anticipates," "believes," "estimates," "expects," "intends," "maintain," "may," "plans," "potential," "strategy," "targets," "will," "would" and other similar terminology is intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words or phrases. The forward-looking statements included in this Form 8-K involve risks and uncertainties that could cause actual results to differ materially from projected results. Accordingly, investors should not place undue reliance on forward-looking statements as a prediction of actual results. The Company has based these forward-looking statements on current expectations and assumptions about future events, including the possibility that the Transaction will not be completed on the terms and conditions, or on the timing, currently contemplated, and that it may not be completed at all, due to a failure to obtain or satisfy, in a timely manner or otherwise, required regulatory, shareholder and court approvals and other conditions to the completion of the Transaction or for other reasons; the risk that competing offers or acquisition proposals will be made; the negative impact that the failure to complete the Transaction for any reason could have on the price of the Common Shares or on the business of the Company; Hanmi Purchaser's failure to pay the cash consideration at com
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 2.1* Arrangement Agreement, dated as of November 18, 2025, by and among Aptose Biosciences Inc., Hanmi Pharmaceuticals Co. Ltd. and HS North America Ltd. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Certain of the exhibit and schedules to this exhibit have been omitted in accordance with Item 601(a)(6) and 601(b)(2)(ii) of Regulation S-K. The Company agrees to furnish supplementally to the Securities and Exchange Commission copy of all omitted exhibits and schedules upon request. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: November 24, 2025 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer